159 results about "Bifidobacterium breve" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses bifidobacterium breve and application thereof in relieving Alzheimer's disease, and belongs to the technical field of probiotics. The preparation method comprises the following steps: separating 18 bifidobacterium strains from feces of children aged 0-3 years old, analyzing and identifying the 18 bifidobacterium strains including bifidobacterium longum, bifidobacterium breve and bifidobacterium animalis, and screening out the bifidobacterium breve LE4 with potential Alzheimer's disease relieving capacity through in-vitro oxidation resistance and LPS (Lipopolysaccharide) removal capacity. The method comprises the steps of behavioral experiments (nesting experiments, open field experiments and water maze experiments), histopathologic analysis, molecular biological detection and the like. The multi-target AD intervention effects of improving the cognitive function, reducing A beta deposition and tau protein phosphorylation, relieving neuroinflammation, enhancing synaptic plasticity, repairing intestinal barriers, adjusting intestinal flora and metabolites and the like of the LE4 strain are comprehensively evaluated, and a new strategy is provided for promoting AD micro-ecological treatment.

The invention relates to a preparation method of a rice leavening with a scalp care effect and a product and application thereof, the preparation method comprises the following steps: mixing a rice raw material, a plant raw material, water, a magnesium salt, a sodium salt and Tween, sterilizing to obtain a fermentation medium, inoculating a compound microbial agent into the fermentation medium, and fermenting to obtain the rice leavening with the scalp care effect. After the fermentation liquid is finished, sterilizing and filtering to obtain a rice leavening; wherein the compound microbial agent comprises a first microbial strain and a second microbial strain; the strains in the first microbial strain comprise a combination of streptococcus thermophilus, bifidobacterium breve and a plant lactobacillus YK-L002 strain; and the second microbial strain comprises a trichosporon YK-S004 strain. According to the invention, specific strains are subjected to compounding and combined fermentation, and the fermentation product filtrate obtained after fermentation treatment of four bacteria has excellent hair care and nourishing effects, and can effectively condition the scalp micro-ecological environment and nourish the hair quality.

The invention discloses a preparation method of high-stability beta-glucan yoghourt. Mixing the sterilized fresh milk with a composite strain consisting of lactobacillus delbrueckii subsp. Bulgaricus, streptococcus salivarius subsp. Thermophilus, bifidobacterium animalis subsp. Lactis, plant lactobacillus, bifidobacterium breve, lactobacillus paracasei, lactobacillus helveticus, lactobacillus rhamnosus and bifidobacterium longum subsp. Longum, and fermenting; and adding beta-glucan into the fermented yoghourt to obtain the high-stability beta-glucan yoghourt. Before beta-glucan is added, the compound bacterial strain is added into the milk, protein in the milk can be gathered under the action of the compound bacterial strain to form a three-dimensional curd network, so that the flowability of a system is reduced, then glucan is added, and the glucan can be uniformly dispersed in curd gaps, so that the glucan is prevented from being excessively combined with the protein in the milk; the stability of a yoghourt system is improved.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The present invention relates to a uric acid-lowering probiotic complex and its application. The probiotic complex comprises Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024; wherein Lactobacillus reuteri FPH2951 is classified as Lactobacillus reuteri and has a deposit number of GDMCC No. 62946; and Bifidobacterium breve FPHC4024 is classified as Bifidobacterium breve and has a deposit number of GDMCC No. 62945. The probiotic complex of the present invention can significantly reduce serum uric acid (UA), creatinine (Cr), and blood urea nitrogen (BUN) levels and increase urine excretion of creatinine (Cr) and blood urea nitrogen (BUN) through the synergistic effect of Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024, and has broad application prospects.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bifidobacterium breve and lactoferrin in preparation of products for regulating intestinal flora or resisting bacterial infection. The invention provides application of Bifidobacterium breve HH079 with the preservation number of GDMCC No: 64216 and lactoferrin in preparation of a product for regulating intestinal flora or a product for resisting bacterial infection, and the Bifidobacterium breve HH079 and the lactoferrin are combined and synergistically used for resisting the bacterial infection. The composition can reverse weight loss, colon shortening, bacterial load increase and colon epithelium injury caused by bacterial infection, can significantly inhibit the level of proinflammatory cytokines, promote the expression of anti-inflammatory cytokines, can significantly increase the concentration of acetic acid and propionic acid in excrement of infected mice, can generate positive regulation on intestinal flora, and can inhibit bacterial infection. Good application prospects are shown in regulation of intestinal flora and bacterial infection resistance.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

Provided are a probiotic formulation for preventing or treating Alzheimer's disease and use thereof. The microorganisms in the probiotic formulation consist of Akkermansia muciniphila and Bifidobacterium breve. Akkermansia muciniphila and Bifidobacterium breve can coordinate with each other after being compounded, so as to provide a synergistic effect on alleviating Alzheimer's disease and thereby a new strategy for preventing or treating Alzheimer's disease. Since Akkermania muciniphila and Bifidobacterium breve are both probiotics, a related functional product prepared from Akkermania muciniphila and Bifidobacterium breve may feature good safety and less likelihood of inducing resistance.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention provides application of bifidobacterium breve in preparation of a product for resisting gastric ulcer and gastric inflammation caused by helicobacter pylori, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve NKU BB1-2 is GDMCC NO: 65956, and the bifidobacterium breve NKU BB1-2 can antagonize helicobacter pylori colonization and relieve gastric ulcer aggravation caused by helicobacter pylori. The bifidobacterium breve NKU BB 1-2 has good helicobacter pylori antagonism ability in an in-vitro environment, and can significantly inhibit colonization growth of helicobacter pylori; animal experiments show that the bifidobacterium breve NKU BB 1-2 can relieve gastric ulcer aggravation caused by helicobacter pylori infection in vivo, and the gastric mucosa lesion is relieved, the stomach inflammation is relieved, and the stomach pH value is increased; in addition, the bifidobacterium breve NKU BB1-2 can also significantly improve the diversity of stomach microorganisms, regulate and improve the structure of the stomach microorganisms, and assist antagonism and removal of helicobacter pylori infection.

The invention belongs to the technical field of fermentation and metagen preparations, and particularly relates to application of bifidobacterium breve metagen in the aspects of scavenging free radicals and relieving oxidative aging. According to the present invention, the oxidative free radical scavenging experiment results show that the bifidobacterium breve NKU BB 1-2 metagen has good oxidative free radical scavenging ability, and has good scavenging ability on hydroxyl free radicals, superoxide anions and DPPH free radicals; meanwhile, through component analysis, it is found that the bifidobacterium breve NKU BB 1-2 metagen contains various antioxidant and anti-aging bioactive substances such as flavonoids, indoles, amino acids, bile acids and ceramides; a cell model experiment verifies that the bifidobacterium breve NKU BB 1-2 metagen can obviously relieve oxidative damage to the cells and improve the oxidation resistance of the cells, so that oxidative aging is relieved.

The invention belongs to the technical field of microorganisms, and relates to a bifidobacterium breve strain capable of relieving constipation, the strain is bifidobacterium breve Bb-PG-14, the classification name of the strain is Bifidobacterium breve, the preservation number is CGMCC No.31861, the preservation time is September 4, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, and the preservation number is CGMCC No.31861. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from excrement of healthy babies, has relatively strong acid resistance, alkali resistance, cholate resistance and artificial simulated gastrointestinal fluid tolerance, and has the characteristics of probiotics.

The present invention provides a nutritional composition comprising at least one lactose-N-fucose pentasaccharide, in particular lactose-N-fucose pentasaccharide-I (LNFP-I) or a combination of lactose-N-fucose pentasaccharide-I (LNFP-I), lactose-N-fucose pentasaccharide-II (LNFP-II) and lactose-N-fucose pentasaccharide-III (LNFP-III), for use in improving brain development and / or cognitive development in a subject. There is also provided a nutritional composition comprising at least one lactose-N-fucopentasaccharide, in particular lactose-N-fucopentasaccharide-I (LNFP-I) or a combination of lactose-N-fucopentasaccharide-I (LNFP-I), lactose-N-fucopentasaccharide-II (LNFP-II) and lactose-N-fucopentasaccharide-III (LNFP-III), and Bifidobacterium bifidobacterium.

The present application relates to the technical field of probiotics, and particularly relates to a Bifidobacterium breve strain and application of the Bifidobacterium breve strain in prevention or treatment of neurodegenerative diseases and neuroinflammation related to neurodegenerative diseases. Bifidobacterium breve ) BKR006, which is preserved in the China General Microbiological Culture Collection Center (CGMCC) (address: No. 1, Xili Beichen, Chaoyang District, Beijing), and the preservation number is CGMCC No. 36096. The strain in the present application is proved in animal experiments that the strain can not only significantly improve the cognitive function and A beta pathology of AD model animals, but also effectively inhibit neuroinflammation in PD models and improve related cognitive impairment, and has a broad spectrum of neuroprotective effect and good development and application prospect.

The invention provides a composition of probiotics and LNT (Lipoprotein Nitrate), wherein the probiotics are selected from one or two of Bifidobacterium breve BB-G95 (Bifidobacterium breve BB-G95) and Bifidobacterium bifidum BB-G90 (Bifidobacterium bifidum BB-G90). The probiotic is capable of efficiently utilizing LNT, so that the composition can be used at least in the following aspects: increasing the metabolic activity of the intestinal microbiota of a subject taking the composition; improving transplantation and / or survival of bifidobacteria in the intestinal tract of a subject taking the composition; promoting the growth and / or survival of beneficial bacteria in the intestinal tract of a subject taking the composition; promoting metabolism of short chain fatty acids in the intestinal tract of a subject taking the composition; treating, preventing and / or reducing inflammation or infection in a subject taking the composition.

The invention relates to a nutritional composition for infants, for children as well as a medical nutritional composition, comprising human milk oligosaccharides and Bifidobacterium breve. The invention further relates to the use of said nutritional composition for strengthening the gut epithelial defense and / or the gut barrier function.

The invention discloses a preparation method of acete chinensis buckwheat noodles, and belongs to the technical field of food processing. The present invention provides an acetes chinensis buckwheat noodle preparation method, which comprises: (1) cleaning fresh acetes chinensis to remove impurities, washing with clear water, adding water, and pulping; then adding fructo-oligosaccharide, and sterilizing to obtain an acete chinensis mixture; (2) adjusting the pH value of the acete chinensis mixture to 3.0-5.0, and simultaneously adding acid protease and bifidobacterium breve for enzymolysis-fermentation treatment; and (3) mixing the acete chinensis pulp obtained after the enzymolysis-fermentation treatment with sweet buckwheat flour, vital gluten, konjaku flour and high-gluten wheat flour, kneading dough, performing extrusion forming, and performing vacuum drying to obtain the final acete chinensis buckwheat noodles. The acete chinensis and buckwheat noodles prepared by the method reduce allergens in acete chinensis, produce nutrient substances through probiotic fermentation, and have good taste.

A cognitive function-improving agent containing one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175 as an active ingredient for administration to a subject who has not developed dementia is provided.

The application belongs to the technical field of microorganisms, and particularly relates to a Bifidobacterium breve RRJK1316 capable of promoting digestion and application thereof. Bifidobacterium breve The Bifidobacterium breve is named as Bifidobacterium breve (RRJK1316), is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No. 64764. The strain has strong acid and bile salt resistance, can effectively resist the influence of gastric juice, and can maintain high activity after passing through the digestive tract. The strain has strong digestion promotion function, and the digestion promotion function is better than that of domperidone 75.0 mu g / mL when the concentration of live bacteria is 6.00*10 8 CFU / mL. Meanwhile, the strain has the function of relieving lactose intolerance, and the beta-galactoside enzyme activity reaches 0.793 U / mL.

The present invention provides a compound probiotic for enhancing immunity and a functional yogurt prepared therefrom. The compound probiotic is composed of Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024. In the present invention, three strains with different properties, namely Lactobacillus helveticus LZ-R-5, Lactobacillus reuteri FPHC2951, and Bifidobacterium breve FPHC4024, are combined in a certain proportion, and a synergistic effect is generated among the three strains, which has significant technical advantages in enhancing immunity. The product of the present invention has high safety, is not prone to generating resistance, and has good safety and application prospects.

The invention discloses a preparation method of zero-lactose yoghurt fermented milk for infants, which specifically comprises the following steps: firstly, performing high-temperature sterilization on raw milk, then cooling, and adding lactase Nola Fit 5500 before fermentation to perform pre-hydrolysis of lactose so as to ensure zero lactose of the product from the source. Then, compound probiotics composed of bifidobacterium animalis subsp. Lactis HN019, lactobacillus mucus fermentation CECT5716, lactobacillus rhamnosus HN001 and bifidobacterium breve M-16V are added, low-temperature slow fermentation is carried out for 15 hours at the temperature of 41 + / -1 DEG C, and no exogenous sugar is added in the whole process. According to the process, nutritional ingredients are reserved to the maximum extent through mild fermentation, formation of natural flavor is promoted, and the obtained product is safe, nutritional and easy to digest and can effectively improve intestinal health of infants and reduce the risk of digestion discomfort.

Provided is a mixed strain with both excellent anti-inflammatory activity and excellent productivity, including Bifidobacterium animalis subsp. lactis LM1017 (Accession No. KCCM12629P), Bifidobacterium n breve LM1092 (Accession No. KCCM13464P), Bifidobacterium longum LM1024 (Accession No. KCCM12919P), and Bifidobacterium bifidum LM1108 (Accession No. KCCM13463P). The strain provided herein has an excellent commercial viability of probiotics.

The invention relates to the technical field of functional foods, in particular to a fermented cereal formula food for controlling sugar and a preparation method thereof, three strains synergistically ferment cereals, and are compounded with a high-activity white hyacinth bean alpha-amylase inhibitor, high-purity mulberry leaf superfine powder and chromium-enriched yeast to jointly construct a multi-way blood sugar regulation and control system; according to the formula, three proteins of soybeans, whey and peas are combined with dietary fibers and prebiotics, the nutritional structure is optimized, satiety is enhanced, traditional herbal essences such as bitter gourds and Chinese yams are supplemented, the dual goals of scientific sugar control and nutrition balance are achieved through precise proportioning, deep biotransformation of cereal nutritional ingredients is achieved through a three-strain staged synergistic fermentation technology, and the nutritional value of the whole grain is improved. According to the present invention, the deep biological conversion of cereal nutritional components is achieved through the protein hydrolysis and glycoside hydrolysis ability of the lactobacillus plantarum, the glutamic acid decarboxylation ability of the bifidobacterium breve, and the vitamin synthesis and chromium enrichment ability of the saccharomyces cerevisiae;

The present invention relates to a low-acid reflux, heat-stable rock sugar syrup and a preparation method thereof, belonging to the technical field of sweeteners. The rock sugar syrup is prepared from the following raw materials in parts by weight: 80 to 90 parts of rock sugar, 0.2 to 0.4 parts of steviol glycosides, 0.5 to 2 parts of maltitol, 0.5 to 2 parts of glucose syrup, 5 to 8 parts of monk fruit extract, 80 to 120 parts of purified water, and sodium citrate. The sodium citrate is used to adjust the pH value of the rock sugar syrup to 5.5 to 6.0. The monk fruit extract is a product obtained by co-fermenting the pulp and peel of fresh monk fruit with Bifidobacterium breve and Pediococcus pentosaceus, and then enzymolyzing it with ficin. The rock sugar syrup of the present invention is added with steviol glycosides and monk fruit extract, which can well maintain the stability of the rock sugar syrup, has good anti-acid reflux properties, and saves the amount of maltitol and glucose syrup.

The present invention provides a strain of Bifidobacterium breve BX-18 and its application, and belongs to the field of biotechnology. The deposit number of Bifidobacterium breve (Bifidobacterium breve) BX-18 provided by the present invention is CGMCCNo.28446. The Bifidobacterium breve BX-18 can synthesize active substances such as amino acids and metabolites thereof, benzene derivatives, flavonoids, and its metabolites have broad-spectrum antibacterial activity and have good antibacterial effect on foodborne pathogens or spoilage bacteria. The present invention provides a new idea for the in-depth study and utilization of probiotics with functional active substances, which has huge research and application value.

The invention relates to the technical field of biological medicines, and aims to provide a novel application of bifidobacterium breve in preparation of a medicine for preventing and / or treating melanoma, and the purpose of preventing and treating melanoma is achieved by changing the immune microenvironment of melanoma by using microorganisms.